Advertisement
Advertisement

MDGL

MDGL logo

Madrigal Pharmaceuticals, Inc. Common Stock

497.27
USD
Sponsored
-18.69
-3.62%
May 29, 16:00 UTC -4
Closed
exchange

After-Market

497.34

+0.07
+0.01%

Madrigal Pharmaceuticals, Inc. Common Stock Profile

About

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Info & Links

CEO

William J. Sibold

Headquarters

200 BARR HARBOR DRIVE, SUITE 200
WEST CONSHOHOCKEN, PA 19428, UNITED STATES

Industry

Medical Drugs

Sector

Medical

Website

www.madrigalpharma.com

Auditor

PricewaterhouseCoopers LLP

Share holders

12

Employees

915

Madrigal Pharmaceuticals, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

11.47B

Enterprise Value

11.57B

Enterprise Value/EBITDA(ttm)

-37.72

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

12.55

Price to Book(mrq)

19.76

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

94.63%

Operating Margin(ttm)

-30.08%

Profit Margin(ttm)

-32.81%

Return on Equity(ttm)

-43.76%

Return on Invested Capital(ttm)

-32.07%

Return on Assets(ttm)

-24.88%

Income Statement

Revenue(ttm)

1.13B

Revenue Per Share(ttm)

49.12

Gross Profit(ttm)

1.05B

EBITDA(ttm)3

-306.82M

Net Income Available to Common(ttm)

-309.44M

Diluted EPS(ttm)

-12.87

Share Statistics

Beta (5Y Monthly)

-1.00

52-Week Change

83.58%

S&P 500 52-Week Change

28.22%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

23.06M

Dividend Yield

0.00%

Float4

18.01M

% Held by Insiders

21.50%

% Held by Institutions

98.50%

Balance Sheet

Total Cash(mrq)

817.93M

Total Cash Per Share(mrq)

35.48

Total Debt(mrq)

340.33M

Total Debt/Equity(mrq)

56.39%

Current Ratio(mrq)

4.01%

Quick Ratio(mrq)

3.77%

Book Value Per Share(mrq)

26.39

Cash Flow

Operating Cash Flow Per Share(ytd)

-8.45

Free Cash Flow(ytd)

-190.02M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement